尊龙凯时人生就是搏·(中国区)官方网站

VOLUNTARY ANNOUNCEMENT - ZONGERTINIB TABLETS APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - DATA FROM FOUR STUDIES OF "TQC3721 (PDE3/4 INHIBITOR)", "TQC2731 (TSLP MONOCLONAL ANTIBODY)" AND "TQC3403 (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE POWDER FOR INHALATION)" PRESENTED AT ERS 2025

VOLUNTARY ANNOUNCEMENT - HER2-SELECTIVE TKI "ZONGERTINIB" ONCE AGAIN GRANTED BREAKTHROUGH THERAPEUTIC DESIGNATION BY CDE

VOLUNTARY ANNOUNCEMENT - LM-302 "CLDN18.2 ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS

Cash Dividend Announcement for Equity Issuer

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3142 “BcL-xL PROTAC”ACCEPTED BY NMPA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3122 "PARP1 INHIBITOR" ACCEPTED BY NMPA